Nexalin Technology Inc [NXL] stock is trading at $2.88, up 10.77%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NXL shares have gain 10.77% over the last week, with a monthly amount drifted -2.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nexalin Technology Inc [NXL] stock has fluctuated between $0.25 and $4.49 over the past year. Nexalin Technology Inc [NASDAQ: NXL] shares were valued at $2.88 at the most recent close of the market.
Analyzing the NXL fundamentals
Nexalin Technology Inc [NASDAQ:NXL] reported sales of 0.16M for the trailing twelve months, which represents a growth of 49.43%. Gross Profit Margin for this corporation currently stands at -5.73% with Operating Profit Margin at -40.13%, Pretax Profit Margin comes in at -34.27%, and Net Profit Margin reading is -34.27%. To continue investigating profitability, this company’s Return on Assets is posted at -1.06, Equity is -1.88 and Total Capital is -1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.46 points at the first support level, and at 2.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.23, and for the 2nd resistance point, it is at 3.57.
Ratios To Look Out For
For context, Nexalin Technology Inc’s Current Ratio is 16.39. In addition, the Quick Ratio stands at 15.86 and the Cash Ratio stands at 0.27. Considering the valuation of this stock, the price to sales ratio is 239.47, the price to book ratio is 7.47.
Transactions by insiders
Recent insider trading involved Owens David, Chief Medical Officer, that happened on Jan 28 ’25 when 1500.0 shares were purchased. Chief Medical Officer, Owens David completed a deal on Jan 13 ’25 to buy 2000.0 shares. Meanwhile, Chief Medical Officer Owens David bought 1000.0 shares on Jan 23 ’25.
